Immuneering (IMRX) Stock Price

Immuneering Price

NASDAQ·CLOSED
3.86
​
Market closed

Revenue at Immuneering has contracted by 87.6% per year over the past 4 years to 455.00 USD. Immuneering's net margin stands at -11,752,005.0%, down from -401.6% several years earlier. Analysts set a median price target of 14.00 USD, implying 262.7% above the current price. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus.

Immuneering stock price

Access this data via the Eulerpool API

Immuneering business model & stock analysis

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. Its platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Frequently asked questions about Immuneering

Analysts currently set an average price target of 14.33 USD for the Immuneering stock (median: 14.00 USD), implying +271.2 % versus the latest price. The consensus is based on 13 analyst ratings.

13 analysts currently rate the Immuneering stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Immuneering to generate revenue of 21.27 M USD and earnings per share of -1.12 USD.

Converted at the current exchange rate, the Immuneering share trades at 3.44 EUR (3.86 USD).

The Immuneering share (IMRX) is listed on 1 stock exchanges, including: NASDAQ (IMRX).

The expected revenue of Immuneering is 21.27 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Immuneering is -72.23 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Immuneering is currently -3.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immuneering stock.

The price-to-sales ratio (P/S) of Immuneering is currently 11.72. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Immuneering stock.

The Eulerpool Quality Score for Immuneering is 2/10.

The ISIN of Immuneering is US45254E1073. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Immuneering is IMRX. The ticker symbol is used to trade Immuneering shares on the stock exchange.

Fair ValueTerminal
3.71 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jul 30, 2021
ISIN
US45254E1073
Cusip
45254E107
Market capitalization
249.24 M USDMicro Cap
52-Week Range
PEG
0.11
P/E ratio
P/Ee 2026
-3.45
P/Ee 2027
-3.07
P/Ee 2028
-3.40
P/Ee 2029
-4.75
P/Ee 2030
-52.55
P/Se
11.72
EV/EBIT
—
P/B Ratio
1.14
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-25.60 %
Last updated Oct 9, 2026, 9:08 AM

Immuneering Peer Group

Immuneering Ticker

NASDAQ · IMRX

Immuneering FIGI

IMRX:US · BBG009QXJQS1IMRX:UA · BBG011R6P997IMRX:UC · BBG011R6P9B4IMRX:UN · BBG011R6P9D2IMRX:UP · BBG011R6P9F0IMRX:UQ · BBG011R6P9G9IMRX:UB · BBG011R6P9H8IMRX:UM · BBG011R6P9K4IMRX:UX · BBG011R6P9L3IMRX:UD · BBG011R6P9R7IMRX:UF · BBG011R6P9V2IMRX:VY · BBG011R6P9W1

All fundamentals and in-depth analysis of Immuneering

Our stock analysis for Immuneering stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuneering. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.